Key Insights

Highlights

Treatment Research

2 treatments under study, led by Biospecimen Sample Collection During Standardofcare Surgery

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Recruiting2
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07377747RecruitingPrimary

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

NCT06436846RecruitingPrimary

Genomic Risk in Retroperitoneal Sarcoma

NCT02587169Phase 1/2UnknownPrimary

Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum

Showing all 3 trials

Research Network

Common Treatments

  • Biospecimen Sample Collection During Standardofcare Surgery1
  • Nilotinibadriamycin1

Active Sponsors

  • Fox Chase Cancer Center1
  • Broto, Javier Martín, M.D.1
  • Australia and New Zealand Sarcoma Association1

Top Investigators

Related Conditions

  • Soft Tissue Sarcoma1
  • Retroperitoneal Leiomyosarcoma1
  • Chondrosarcoma1

Activity Timeline